Healthy Clinical Trial
Official title:
A Phase 1 Cross-over Study to Determine Food Effects on the Pharmacokinetics of Oral BTD-001 and Metabolites in Healthy Volunteers, Followed by an Optional Multiple Dose Study to Assess Pharmacokinetics of Oral BTD-001
Verified date | October 2017 |
Source | Balance Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating
females. The study will consist of up to 2 parts; the decision to proceed to the optional
second part will be made following review of Part 1 data.
Part 1 is a single dose, two period crossover to assess food affect of oral BTD-001.
Optional Part 2 is a non-randomised, single arm study multi dose design to evaluate PK
profile of BTD-001
Status | Completed |
Enrollment | 12 |
Est. completion date | July 12, 2017 |
Est. primary completion date | July 12, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Healthy adult males and non-pregnant, non-lactating females aged 18-55 years old - BMI between18.0-35.0 kg/m2 unless investigator deems not clinically significant - Provide written consent - Agrees to protocol specified contraception Exclusion Criteria: - Received any investigational treatment within last 3 months - Subjects who are study site employees, or immediate family members of a study site or sponsor employee - Subjects who have previously been enrolled in this study - History of any drug or alcohol abuse in the past 2 years - Regular alcohol consumption in males >21 units per week - Current smokers and those who have smoked, including nicotine replacement or e-cigarates within the last 12 months. - Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening - Clinically significant abnormal lab results - Positive drugs of abuse test result - Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results - Evidence of renal impairment at screening - History of or current seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years - Clinically significant medical/psychiatric history findings, or physical/neurological examination findings or significant history of or current suicidal ideation or behaviour - History of or current significant pulmonary, cardiac, renal, hepatic, chronic respiratory, gastrointestinal, neurological or psychiatric disease, substance dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal cell carcinomas or local cervical squamous cell cancer resolved after resection) or hypothyroidism - Subjects with QT interval corrected for heart rate according to Fridericia's formula of >430 msec in males and >450 msec in females - Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients - Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active - Donation or loss of greater than 400 mL of blood within the previous 3 months Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol,hormone replacement therapy and hormonal contraception) or herbal remedies - Failure to satisfy the investigator of fitness to participate for any other reason |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Quotient Clinical | Ruddington | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Balance Therapeutics |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Karolinska Sleepiness Scale | To assess sleepiness using the KSS | [Maximum 30 days] | |
Primary | Part 1 & Part 2 - Cmax of BTD-001 and major metabolites | Maximum Observed Plasma Concentration | [Maximum 30 days] | |
Primary | Part 1 & Part 2 - Tmax of BTD-001 and major metabolites | Time to Maximum Observed Plasma Concentration | [Maximum 30 days] | |
Primary | Part 1 & Part 2 - AUC(0-last): of BTD-001 and major metabolites | Area Under the Curve for Observed Plasma Concentration | [Maximum 30 days] | |
Primary | Part 1 & Part 2 - T1/2 of BTD-001 and major metabolites | elimination half-life | [Maximum 30 days] | |
Secondary | Physical Examination | Safety and tolerability of BTD-001 by assessing physical examination | [Maximum 30 days] | |
Secondary | Vital Signs | Safety and tolerability of BTD-001 by assessing vital signs | [Maximum 30 days] | |
Secondary | ECG | Safety and tolerability of BTD-001 by assessing ECG | [Maximum 30 days] | |
Secondary | Adverse Events | Safety and tolerability of BTD-001 by assessing AEs | [Maximum 30 days] | |
Secondary | Safety Lab Test | Safety and tolerability of BTD-001 by assessing safety lab tests | [Maximum 30 days] | |
Secondary | Likert Scales | To assess BTD-001 withdrawal in healthy volunteers | [Maximum 30 days] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |